Larimar Therapeutics (LRMR) Non-Current Debt (2014 - 2020)

Larimar Therapeutics' Non-Current Debt history runs 7 years deep, the most recent figure standing at $6.7 million for Q1 2020.

• Quarterly Non-Current Debt fell 50.12% year-over-year to $6.7 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $6.7 million (down 50.12% YoY) and the FY2019 annual result came in at $8.5 million, down 44.26% from the prior year.
• Non-Current Debt was $6.7 million for Q1 2020 at Larimar Therapeutics, down from $8.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $20.5 million in Q3 2018 and bottomed at $1.2 million in Q3 2016.
• A 5-year average of $11.6 million and a median of $11.9 million in 2019 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2016 — Non-Current Debt sank 71.17% — and 2018, when it dropped 24.08%.
• Larimar Therapeutics' Non-Current Debt stood at $1.2 million in 2016, then jumped by 1566.67% to $20.0 million in 2017, then dropped by 24.08% to $15.2 million in 2018, then plunged by 44.26% to $8.5 million in 2019, then retreated by 20.29% to $6.7 million in 2020.
• Business Quant data shows LRMR's Non-Current Debt at $6.7 million in Q1 2020, $8.5 million in Q4 2019, and $10.2 million in Q3 2019.